Trials / Conditions / Refractory Ewing Sarcoma

Refractory Ewing Sarcoma

13 registered clinical trials studyying Refractory Ewing Sarcoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sa NCT05734066	Jazz Pharmaceuticals	Phase 1 / Phase 2
Active Not Recruiting	Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors NCT05071209	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119	Children's Oncology Group	Phase 1 / Phase 2
Recruiting	Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702	St. Jude Children's Research Hospital	Phase 1 / Phase 2
Active Not Recruiting	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888	National Cancer Institute (NCI)	Phase 2
Completed	Cabozantinib With Topotecan-Cyclophosphamide NCT04661852	Dana-Farber Cancer Institute	Phase 1
Active Not Recruiting	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994	National Cancer Institute (NCI)	Phase 2
Completed	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592	National Cancer Institute (NCI)	Phase 2
Completed	Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma NCT02546544	University of Oxford	Phase 2